Corvus Pharmaceuticals, Inc. — Director's Dealing 2016

Mar 22, 2016

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Corvus Pharmaceuticals, Inc. (CRVS)
CIK: 0001626971
Period of Report: 2016-03-22

Reporting Person: Morrison Scott W (Director)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$15.79	2025-12-30	Common Stock (30000)		Direct

Footnotes

F1: The underlying shares subject to the option vest and become exercisable as to one-third (1/3rd) of the shares subject to the option on each annual anniversary measured from December 31, 2015, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.